Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response William L. Ledger, Bart C.J.M. Fauser, Paul.

Slides:

Advertisements

Similar presentations

Effect of androgen supplementation or modulation on ovarian stimulation outcome in poor responders: a meta-analysis Sesh Kamal Sunkara, Jyotsna Pundir,

Advertisements

Cancer and fertility: strategies to preserve fertility

Kay Neumann, Georg Griesinger Reproductive BioMedicine Online

Vuong Thi Ngoc Lan, Nguyen Khanh Linh, Ho Manh Tuong, P. C

Live births after management of severe OHSS by GnRH antagonist administration in the luteal phase TG Lainas, IA Sfontouris, IZ Zorzovilis, GK Petsas,

J. C. Castillo, M. Dolz, E. Bienvenido, L. Abad, E. M. Casañ, F

J. C. Castillo, M. Dolz, E. Bienvenido, L. Abad, E. M. Casañ, F

HP-HMG versus rFSH in treatments combining fresh and frozen IVF cycles: success rates and economic evaluation Jaro Wex-Wechowski, Ahmed M. Abou-Setta,

Higher β-HCG concentrations and higher birthweights ensue from single vitrified embryo transfers Kevin N. Keane, Kamarul Bahyah Mustafa, Peter Hinchliffe,

Genetic variants associated with female reproductive ageing – potential markers for assessing ovarian function and ovarian stimulation outcome Triin.

Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF Bart C.J.M. Fauser, Michael.

Preovulatory progesterone concentration associates significantly to follicle number and LH concentration but not to pregnancy rate Claus Yding Andersen,

Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction Antonio La Marca, Giovanni D’Ippolito

N. la Cour Freiesleben, T. A. Gerds, J. L. Forman, J. D. Silver, A

Advanced glycation end product concentrations in follicular fluid of women undergoing IVF/ICSI with a GnRH agonist protocol Qi Yao, Yuanjiao Liang, Yong.

No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH George Griesinger, Daniel B. Shapiro, Efstratios.

Anti-Müllerian hormone for the assessment of ovarian response in GnRH-antagonist- treated oocyte donors Nikolaos P. Polyzos, Dominic Stoop, Christophe.

Oestradiol valerate pretreatment in GnRH-antagonist cycles: a randomized controlled trial Christophe Blockeel, Sara Engels, Michel De Vos, Patrick Haentjens,

Patient-tailored ovarian stimulation for in vitro fertilization

A. La Marca, G. Sighinolfi, S. Giulini, M. Traglia, C. Argento, C

In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation

Ovarian response to 150 µg corifollitropin alfa in a GnRH-antagonist multiple-dose protocol: a prospective cohort study Tamara Lerman, Marion Depenbusch,

Circulating concentration of stem cell factor in serum of stimulated IVF patients Ali Salmassi, Sandy Zorn, Liselotte Mettler, Kerstin Koch, Walter Jonat,

HDlive ultrasound images in assisted reproduction treatment

New strategies of ovarian stimulation based on the concept of ovarian follicular waves: From conventional to random and double stimulation Giovanna Sighinolfi,

Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective.

Anti-Müllerian hormone as an independent predictor of twin versus singleton pregnancy in fresh cycles Reshef Tal, David B. Seifer, Moisey Khanimov, Eliana.

Diagnostic application of oxidation-reduction potential assay for measurement of oxidative stress: clinical utility in male factor infertility Ashok.

Utility of age-specific serum anti-Müllerian hormone concentrations

Biosimilars to recombinant human FSH medicines: comparable efficacy and safety to the original biologic Fernando de Mora, Bart C.J.M. Fauser Reproductive.

Sarah McCredie, William Ledger, Christos A. Venetis

Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.

Ongoing pregnancies from early retrieval of prematurely developing antral follicles after DHEA supplementation Murat Sönmezer, Aylin Pelin Çil, Kutluk.

Chief editor's 2017 annual report

Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis Georg Griesinger, Robert Boostanfar, Keith.

Ovarian reserve determinations suggest new function of FMR1 (fragile X gene) in regulating ovarian ageing Norbert Gleicher, Andrea Weghofer, David H.

M. Dieterich, M. Bolz, T. Reimer, S. Costagliola, B. Gerber

Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa F. Olivennes, G. Trew,

Reproductive BioMedicine Online

Steroid profiles by liquid chromatography-mass spectrometry of matched serum and single dominant ovarian follicular fluid from women undergoing IVF Kirsty.

Sequential use of letrozole and gonadotrophin in women with poor ovarian reserve: a randomized controlled trial Vivian Chi Yan Lee, Carina Chi Wai Chan,

John L. Yovich, Kevin N. Keane, Gayatri Borude, Satvinder S

Myotonic dystrophy type 1 and PGD: ovarian stimulation response and correlation analysis between ovarian reserve and genotype C. Dechanet, C. Castelli,

Follicular flushing in natural cycle IVF does not affect the luteal phase – a prospective controlled study M. von Wolff, A. Kohl Schwartz, P. Stute,

Impact of vitamin D levels on ovarian reserve and ovarian response to ovarian stimulation in oocyte donors Alberta Maria Fabris, Maria Cruz, Carlos Iglesias,

Follicular and endocrine profiles associated with different GnRH-antagonist regimens: a randomized controlled trial Juan Antonio García-Velasco, Sanja.

A unique biological in-vivo model to evaluate follicular development during in-vitro maturation treatment S.E. Elizur, W.Y. Son, H. Clarke, D. Morris,

V Isachenko, E Isachenko, R Kreienberg, M Woriedh, JM Weiss

Michael J. Levy, William Ledger, Efstratios M. Kolibianakis, Pieta C

LH concentrations do not correlate with pregnancy in rFSH/GnRH antagonist cycles Kevin Doody, Paul Devroey, Keith Gordon, Han Witjes, Bernadette Mannaerts

A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin.

Does ovarian stimulation regimen affect IVF outcome

Anna Pia Ferraretti, Paul Devroey, M. Cristina Magli, Luca Gianaroli

Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature Micah J. Hill, Gary Levy, Eric D. Levens

Genome-wide analysis shows no genomic predictors of ovarian response to stimulation by exogenous FSH for IVF Jeroen van Disseldorp, Lude Franke, Rene.

FMR1 and AKT/mTOR signalling pathways: potential functional interactions controlling folliculogenesis in human granulosa cells Julia Rehnitz, Diego D.

Is parental consanguinity associated with reduced ovarian reserve?

Progesterone elevation on the day of HCG administration may affect rescue ICSI Bo Huang, Zhou Li, Lixia Zhu, Dan Hu, Qun Liu, Guijin Zhu, Hanwang Zhang

Factors related to successful ovulation induction in patients with WHO group II anovulatory infertility C.M. Howles, V. Alam, D. Tredway, R. Homburg,

Nadine M. P. Daan, Annemieke Hoek, Eva Corpeleijn, Marinus J. C

Norbert Gleicher, Andrea Weghofer, David H. Barad

Predictive value of ovarian reserve markers in smoking and non-smoking women undergoing IVF Thomas Freour, Lionel Dessolle, Miguel Jean, Damien Masson,

Ovarian reserve screening before contraception?

Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH Basil C. Tarlatzis,

Orhan Bukulmez, M. D. , Bruce R. Carr, M. D. , Kathleen M. Doody, M. D

John Yovich, James Stanger, Peter Hinchliffe

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

Intensified ovarian stimulation in a GnRH antagonist protocol with agonist triggering: a prospective, clinical feasibility study Georg Griesinger, Henriette.

First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.

Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era? Antonio La Marca, Martina Capuzzo Reproductive.

Presentation transcript:

Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response William L. Ledger, Bart C.J.M. Fauser, Paul Devroey, Anthe S. Zandvliet, Bernadette M.J.L. Mannaerts Reproductive BioMedicine Online Volume 23, Issue 2, Pages 150-159 (August 2011) DOI: 10.1016/j.rbmo.2011.04.002 Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

Figure 1 Schematic representation of the therapeutic interventions in the corifollitropin alfa treatment regimen in relation to immunoreactivity measured by FSH immunoassay. GnRH=gonadotrophin-releasing hormone; HCG=human chorionic gonadotrophin; rFSH = recombinant FSH. Reproductive BioMedicine Online 2011 23, 150-159DOI: (10.1016/j.rbmo.2011.04.002) Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

Figure 2 Relationship between dose-normalized drug exposure to corifollitropin alfa (exposure to corifollitropin alfa normalized to the administered dose, dose normalized area under the curve (AUC)) and patient body weight. Reproductive BioMedicine Online 2011 23, 150-159DOI: (10.1016/j.rbmo.2011.04.002) Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

Figure 3 Relationship between mean number of oocytes per started cycle and dose of corifollitropin alfa: (A) 100μg for subjects ⩽60kg and (B) 150μg for subjects >60kg. Adapted from de Greef et al. (2010). Reproductive BioMedicine Online 2011 23, 150-159DOI: (10.1016/j.rbmo.2011.04.002) Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

Figure 4 Exposure to corifollitropin alfa (AUC) in Caucasian subjects. Horizontal white marks represent median values, boxes represent interquartile ranges and whiskers represent 5–95th percentiles. Pharmacokinetic parameters obtained by population pharmacokinetic analysis. Reproductive BioMedicine Online 2011 23, 150-159DOI: (10.1016/j.rbmo.2011.04.002) Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

Figure 5 Relationship between number of oocytes and potential predictors of ovarian response in Caucasian subjects after treatment with recommended dose of corifollitropin alfa: number of oocytes versus (A) AUC; (B) Cmax; (C) body weight; (D) basal FSH; (E) AFC; and (F) age. AFC = antral follicle count; AUC = area under curve; CI = confidence intervals; Cmax = peak serum concentration; P=percentile. Reproductive BioMedicine Online 2011 23, 150-159DOI: (10.1016/j.rbmo.2011.04.002) Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

Figure 6 Time profiles of the corifollitropin alfa serum concentration after administration of a recommended (green), too low (orange) or too high (red) dose of corifollitropin alfa. The arrows indicate the time point when follicular stimulation is no longer sustained by a single s.c. dose of corifollitropin alfa. PK=pharmacokinetic. Reproductive BioMedicine Online 2011 23, 150-159DOI: (10.1016/j.rbmo.2011.04.002) Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions